Oral GLP-1 drugs may quiet the brain’s food craving circuit

Popular weight-loss and diabetes medications such as semaglutide and Ozempic belong to a broader group known as GLP-1 drugs. A study funded by the National Institutes of Health (NIH) has now identified a previously unrecognized way that some newer oral drugs in this class may affect the brain.